Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30464974 | 1.00 | PTGS2 (0.37) | PTGS2PTGS1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL4371685 | 0.77 | NT5E (0.39) | PTGS2PTGS1KDM4ETRPV4PDE2A | |
| SCHEMBL1584056 | 0.77 | NOS3 (0.44) | PTGS2PTGS1HSP90AA1HSP90AB1KDM4E | |
| Ammonia Solution, Strong SCHEMBL27852366 | 0.76 | NOS3 (0.43) | PTGS2PTGS1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL19450884 | 0.76 | HSP90AA1 (0.36) | PTGS2PTGS1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL23162813 | 0.76 | KDM4E (0.37) | PTGS2PTGS1KDM4ETRPV4NT5E | |
| SCHEMBL29760329 | 0.76 | KDM4E (0.37) | PTGS2PTGS1KDM4ETRPV4NT5E | |
| SCHEMBL19155972 | 0.76 | LMNA (0.36) | PTGS2PTGS1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL755969 | 0.76 | HSP90AA1 (0.36) | PTGS2PTGS1HSP90AA1HSP90AB1KDM4E | |
| SCHEMBL13990575 | 0.75 | XPO1 (0.35) | PTGS2PTGS1KDM4ETRPV4NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4228761-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | University College Cardiff Consultants Limited (GB) | 2023-08-23 | — | — | EP | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116472042-A | 2-oxo-dihydroquinoline-3-carboxamide derivatives as modulators of GABA A type receptors | 加的夫大学学院咨询有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | InventisBio Co., Ltd. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-7598392-B2 | 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-10-06 | — | — | US | disclosed |
| CN-101379048-A | Benzo oxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-03-04 | — | — | CN | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259847-A1 | 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof | PKD2, TPMT, PKD1 | PTGS2 901/4885PTGS1 1670/4885HSP90AA1 3045/4885 |
| US-20230357260-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF | TGFB1, TGFB2, TGFBR1 | PTGS2 513/4885PTGS1 122/4885HSP90AA1 1452/4885 |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | GABRA2, GABRA3, GABRB2 | PTGS2 1302/4885PTGS1 1658/4885HSP90AA1 2114/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | PTGS2 1867/4885PTGS1 1655/4885HSP90AA1 2769/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PTGS2 1845/4885PTGS1 1624/4885HSP90AA1 2743/4885 |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | PTGS2 480/4885PTGS1 442/4885HSP90AA1 2295/4885 |
| US-11691981-B2 | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof | TGFB1, TGFB2, TGFBR1 | PTGS2 513/4885PTGS1 122/4885HSP90AA1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.